Brentuximab Chimeric Monoclonal Antibody
Brentuximabis a research-grade recombinant antibody targeting CD30L. Produced in mammalian cells with native-like glycosylation. Highlights Research Grade: For PK/PD studies, assay development, and ADA research. Native Glycosylation: Mammalian expression ensures native-like patterns.
Product Specifications
Product Name Alternative
CD30L receptor, Ki-1 antigen, CD30, TNFRSF8, D1S166E, Tumor necrosis factor receptor superfamily member 8, Lymphocyte activation antigen CD30
UniProt
P28908
Reactivity
Human
Clonality
Monoclonal
Conjugation
Unconjugated
Purification
Protein A/G purified from cell culture supernatant.
Concentration
Lot dependent
Purity
>95% purity as determined by SDS-PAGE.
Form
Liquid
Storage Conditions
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Notes
For research use only.
Tested Applications
ELISA, FA, FACS, In vivo
Host or Source
Chimeric
Preservative
0.01M PBS, pH 7.4.
Isotype
IgG1-kappa
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD106 / VCAM1 (1.4C3), CF640R conjugate, 0.1mg/mL
CD100 (Semaphorin-4D) (A8), CF594 conjugate, 0.1mg/mL
